Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Daily News

Body Fat Distribution Influences Cardiovascular Age

Todd Neale

August 22, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

Todd Neale

October 11, 2023

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

AHA Stresses Benefit of Meds, Surgery for Obesity-Related Hypertension

Yael L. Maxwell

September 23, 2021

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

Michael O'Riordan

March 08, 2017

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

AI-Supported Coaching Shows Promise for Improving Glycemic Control

Body Fat Distribution Influences Cardiovascular Age

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

December 2024 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

AHA Stresses Benefit of Meds, Surgery for Obesity-Related Hypertension

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

A Deadly Diet: Half of US Deaths From Cardiometabolic Causes Linked to Dietary Habits

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content